Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 66

1.

Randomized trial of medroxyprogesterone acetate for the prevention of endometrial pathology from adjuvant tamoxifen for breast cancer: SWOG S9630.

Potkul RK, Unger JM, Livingston RB, Crew KD, Wilczynski SP, Salomon CG, Smith BL, Wong L, Campbell DL, Einspahr DE, Anderson GL, Hershman D, Goodman GE, Brown PH, Meyskens FL, Albain KS.

NPJ Breast Cancer. 2016 Aug 10;2:16024. doi: 10.1038/npjbcancer.2016.24. eCollection 2016.

2.

The ATAC adjuvant breast cancer trial in postmenopausal women: baseline endometrial subprotocol data.

Duffy S, Jackson TL, Lansdown M, Philips K, Wells M, Pollard S, Clack G, Cuzick J, Coibion M, Bianco AR.

BJOG. 2003 Dec;110(12):1099-106.

3.

Prevalence of endometrial proliferation in pipelle biopsies in tamoxifen-treated postmenopausal women with breast cancer in Kuwait.

Al-Azemi M, Labib NS, Motawy MM, Temmim L, Moussa MA, Omu AE.

Med Princ Pract. 2004 Jan-Feb;13(1):30-4.

4.

Pretreatment and prospective assessment of endometrium in menopausal women taking tamoxifen for breast cancer.

Garuti G, Grossi F, Centinaio G, Sita G, Nalli G, Luerti M.

Eur J Obstet Gynecol Reprod Biol. 2007 May;132(1):101-6. Epub 2006 May 5.

PMID:
16678960
5.

Prospective endometrial assessment of breast cancer patients treated with third generation aromatase inhibitors.

Garuti G, Cellani F, Centinaio G, Montanari G, Nalli G, Luerti M.

Gynecol Oncol. 2006 Nov;103(2):599-603. Epub 2006 Jun 5.

PMID:
16750259
6.

The ATAC ('Arimidex', Tamoxifen, Alone or in Combination) adjuvant breast cancer trial: baseline endometrial sub-protocol data on the effectiveness of transvaginal ultrasonography and diagnostic hysteroscopy.

Duffy S, Jackson TL, Lansdown M, Philips K, Wells M, Pollard S, Clack G, Coibion M, Bianco AR; ATAC Trialists' Group.

Hum Reprod. 2005 Jan;20(1):294-301. Epub 2004 Oct 28.

PMID:
15513977
7.

High-dose oral medroxyprogesterone acetate or tamoxifen as adjuvant hormone therapy for node-negative early-stage breast cancer: randomized trial with 7-year update.

Focan C, Beauduin M, Majois F, Canon JL, Cusumano G, Focan-Henrard D, Lobelle JP; Adjuvant Breast Cancer Project, Belgium.

Clin Breast Cancer. 2004 Jun;5(2):136-41.

PMID:
15245618
8.

Effect of tamoxifen on postmenopausal endometrium.

Kalampokas T, Sofoudis C, Anastasopoulos C, Boutas I, Melloy S, Kondi-Pafiti A, Kalampokas E, Botsis D, Salakos N.

Eur J Gynaecol Oncol. 2013;34(4):325-8.

PMID:
24020139
9.

Medroxyprogesterone acetate addition or substitution for tamoxifen in advanced tamoxifen-resistant breast cancer: a phase III randomized trial. Australian-New Zealand Breast Cancer Trials Group.

Byrne MJ, Gebski V, Forbes J, Tattersall MH, Simes RJ, Coates AS, Dewar J, Lunn M, Flower C, Gill PG, Stewart J.

J Clin Oncol. 1997 Sep;15(9):3141-8.

PMID:
9294477
10.

Effects of adjuvant tamoxifen on the endometrium in postmenopausal women with breast cancer: a prospective long-term study using transvaginal ultrasound.

Gerber B, Krause A, Müller H, Reimer T, Külz T, Makovitzky J, Kundt G, Friese K.

J Clin Oncol. 2000 Oct 15;18(20):3464-70.

PMID:
11032586
11.

Tibolone histology of the endometrium and breast endpoints study: design of the trial and endometrial histology at baseline in postmenopausal women.

Archer DF, Hendrix S, Ferenczy A, Felix J, Gallagher JC, Rymer J, Skouby SO, den Hollander W, Stathopoulos V, Helmond FA; THEBES Study Group.

Fertil Steril. 2007 Oct;88(4):866-78. Epub 2007 Jun 4.

PMID:
17548089
12.

Endometrial effects of exemestane compared to tamoxifen within the Tamoxifen Exemestane Adjuvant Multicenter (TEAM) trial: results of a prospective gynecological ultrasound substudy.

Kieback DG, Harbeck N, Bauer W, Hadji P, Weyer G, Menschik T, Hasenburg A.

Gynecol Oncol. 2010 Dec;119(3):500-5. doi: 10.1016/j.ygyno.2010.08.006. Epub 2010 Sep 15.

PMID:
20832103
13.

Anastrozole versus tamoxifen treatment in postmenopausal women with endocrine-responsive breast cancer and tamoxifen-induced endometrial pathology.

Gerber B, Krause A, Reimer T, Mylonas I, Makovitzky J, Kundt G, Janni W.

Clin Cancer Res. 2006 Feb 15;12(4):1245-50.

14.

Endometrial pathology of 104 postmenopausal breast cancer patients treated with tamoxifen.

Ozşener S, Ozaran A, Itil I, Dikmen Y.

Eur J Gynaecol Oncol. 1998;19(6):580-3.

PMID:
10215447
15.

Prospective study on gynaecological effects of two antioestrogens tamoxifen and toremifene in postmenopausal women.

Marttunen MB, Cacciatore B, Hietanen P, Pyrhönen S, Tiitinen A, Wahlström T, Ylikorkala O.

Br J Cancer. 2001 Apr 6;84(7):897-902.

16.

Tamoxifen use and endometrial lesions: hysteroscopic, histological, and immunohistochemical findings in postmenopausal women with breast cancer.

Dibi RP, Zettler CG, Pessini SA, Ayub AV, de Almeida SB, da Silveira GP.

Menopause. 2009 Mar-Apr;16(2):293-300. doi: 10.1097/gme.0b013e31818af10a.

PMID:
19034048
17.

Value of the progesterone test in screening for endometrial pathology in asymptomatic postmenopausal women receiving treatment with tamoxifen.

Lubian López DM, Fernandez YG, Rodríguez BR, López FM, Delgado RC.

Menopause. 2010 May-Jun;17(3):487-93.

PMID:
20464783
18.

Endometrial evaluation in postmenopausal breast cancer patients receiving tamoxifen: an ultrasound, color flow Doppler, hysteroscopic and histological study.

Exacoustos C, Zupi E, Cangi B, Chiaretti M, Arduini D, Romanini C.

Ultrasound Obstet Gynecol. 1995 Dec;6(6):435-42.

19.

Effect of adjuvant tamoxifen on the endometrium in women with breast cancer: a prospective study using office endometrial biopsy.

Barakat RR, Gilewski TA, Almadrones L, Saigo PE, Venkatraman E, Hudis C, Hoskins WJ.

J Clin Oncol. 2000 Oct 15;18(20):3459-63.

PMID:
11032585
20.

The effect of tamoxifen on the endometrium, serum lipids and hypothalamus pituitary axis in the postmenopausal breast cancer patients.

Kavak ZN, Binöz S, Ceyhan N, Pekin S.

Acta Obstet Gynecol Scand. 2000 Jul;79(7):604-7.

PMID:
10929963

Supplemental Content

Support Center